48 pg/mL; range, 151.35–4297.62)

than in the 24 who did not (median, 549.71 pg/mL; range, 209.66–1768.81) (P = 0.097). Of the 67 patients with IL28B TT, 53 achieved RVR, 11 did not and three were undetermined. Of the 27 patients with IL28B non-TT, 15 achieved RVR and 12 did not. RVR rate was significantly higher in patients with IL28B TT than non-TT genotypes (82.8% [53/64] vs 55.6% [15/27], P = 0.009). www.selleckchem.com/products/azd5363.html ETR (92.5% [62/67] vs 59.3% [16/27], P < 0.001) and SVR12 (84.6% [55/65] vs 48.1% [13/27], P = 0.001) rates were also significantly higher in patients with IL28B TT than non-TT genotypes. All three patients not evaluated for IL28B SNP achieved RVR, ETR and SVR12. Of 38 treatment-naïve patients, 31 (81.6%) each achieved RVR and SVR12. Of the 39 relapsers, three were not evaluated for RVR and two for SVR12. RVR was achieved by 29 of 36 evaluable patients (80.6%) and SVR12 by 31 of 37 (83.8%). Of the 20 non-responders, 11 (55%) achieved RVR and nine (45.0%) achieved SVR12. Patients were dichotomized relative to the median IP-10 concentration (461.83 pg/mL), with those having 460 pg/mL or more, and those with less than 460 pg/mL IP-10, defined as the high and low IP-10 groups, respectively. Of check details the 35 IL28B TT patients with low IP-10, 31 (88.6%) achieved RVR (31/35), and of the 29 IL28B TT patients

with high IP-10, 22 (75.9%) achieved RVR (P = 0.203). Of the 11 IL28B non-TT patients with low IP-10, 10 (90.9%) achieved RVR (10/11), whereas, of the 16 IL28B non-TT patients

with high IP-10, five (31.3%) achieved RVR (P = 0.005), indicating that IP-10 concentration was predictive of RVR in patients with IL28B non-TT genotypes. SVR12 rates were similar in IL28B TT patients with low (85.3% [29/34]) and high (83.9% [26/31]) baseline IP-10 (P > 0.999), as well as in IL28B non-TT patients with low (63.6% [7/11]) and high (37.5% [6/16]) IP-10 (P = 0.252). Univariate analysis showed that HCV RNA of 6.8 log IU/mL or more (P = 0.041), IL28B genotype (P = 0.009) and IP-10 concentration (P = 0.001) were significant baseline predictors of RVR (Table 2). Multivariate analysis involving four factors with P < 0.1 in univariate analysis Clomifene showed that IL28B genotype (P = 0.025) and IP-10 concentration (P = 0.004) were independent predictors of RVR. The hazard ratios (HR) and 95% CI for these factors are detailed in Table 2. Univariate analysis showed that liver histology (F0–2 vs F3/4; P = 0.034), RVR (P < 0.001), IL28B genotype (P = 0.001) and discontinuation of all study drugs (P < 0.001) were significant predictors of SVR12 (Table 3). Multivariate analysis involving four factors (only pretreatment factors) with P < 0.1 in univariate analysis showed that IL28B genotype (P = 0.001) and platelet count (P = 0.035) were significant predictors of SVR12.